**Abstract**

**Background:** Mood disorders are being increasingly recognized as having a strong association with chronic inflammatory states. Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMP) are inflammation-related molecules. The major MMPs, MMP-2, -9, and TIMP-2, -1, are inflammatory-related molecules that likely have key roles in mood disorders. The current study sought an association between mood disorders and systemic levels of MMPs and TIMPs.

**Methods:** Serum was obtained from patients with mood disorders (MD) (N = 21) and patients with schizophrenia (SCZ) (N = 13) scheduled to undergo electroconvulsive therapy (ECT). Serum was also obtained from healthy controls (N = 40). Clinical symptoms were assessed by the Hamilton Rating Score for Depression and the Brief Psychiatric Rating Scale. Serum levels of MMPs and TIMPs were quantified by enzyme-linked immunosorbent assay.

**Results:** The serum levels of MMP-2 in MD patients, but not in SCZ patients, prior to the first ECT session (baseline), were significantly lower than those of healthy controls. At baseline, levels of MMP-9 and TIMP-2, -1 were not different between patients with MD, SCZ and healthy controls. After a course of ECT, MMP-2 levels were significantly increased in MD patients but MMP-9 levels significantly decreased in both MD and SCZ patients. In MD patients, there was a significant negative correlation between depressive symptoms and serum levels of MMP-2 and a positive correlation between depressive symptoms and MMP-9. In addition, alterations of serum levels of MMP-2 and 9 were significantly correlated each other and were associated with certain depressive symptoms.

**Conclusion:** A change in inflammatory homeostasis, as indicated by MMP-2 and MMP-9, could be related to mood disorders and these markers appear to be sensitive to ECT.
